Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Sonoma County is among 50 counties due to implement CARE Court by Dec. 1. The program is meant to address the state’s most ...

Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

(RTTNews) - Intra-Cellular Therapies, Inc. (ITCI), Tuesday announced positive data from phase 3 trial of Lumateperone, marketed as Caplyta, for the prevention of relapse in adult patients with ...

Intra-Cellular Therapies has announced positive results from Study 304 evaluating the efficacy and safety of Caplyta (lumateperone) 42mg for the prevention of relapse in adult patients with ...

Medically reviewed by Kathleen Daly, MD Schizoid personality disorder (ScPD) causes traits like having few social ...

For years, due to untreated schizophrenia, I refused housing, preferring to be homeless. When dealing with the severely ...

Are family-based interventions effective and safe for people with schizophrenia and their families, compared with standard care?

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Recently approved xanomeline and trospium chloride (Cobenfy) demonstrated long-term efficacy and safety in patients with ...

Two new studies and an accompanying short film have described the experiences of racially minoritized groups with physical and mental health conditions during the pandemic, depicting the inequalities ...